DBN1 and neoplasm: Next, we examined the band trailing of Drebrin of tumor tissues in different administration groups under non‐reducing conditions and found that the band trailing of Drebrin was stronger in the combined administration group than in the BAY‐876 treatment group (Figure 6J).